Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorYap, Timothy A.
dc.contributor.authorVieito Villar, Maria
dc.contributor.authorBaldini, Capucine
dc.contributor.authorSepúlveda, Juan Manuel
dc.contributor.authorKondo, Shunsuke
dc.contributor.authorSimonelli, Matteo
dc.date.accessioned2022-01-27T09:59:39Z
dc.date.available2022-01-27T09:59:39Z
dc.date.issued2021-12
dc.identifier.citationYap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, et al. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. 2021 Dec;27(24):6666–76.
dc.identifier.issn1557-3265
dc.identifier.urihttp://hdl.handle.net/11351/6913
dc.descriptionCàncer avançat; Factor de creixement transformador beta
dc.language.isoeng
dc.publisherAmerican Association for Cancer Research
dc.relation.ispartofseriesClinical Cancer Research;27(24)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectQuimioteràpia combinada
dc.subjectCàncer - Quimioteràpia - Complicacions
dc.subjectMedicaments - Efectes secundaris
dc.subject.meshNeoplasms
dc.subject.mesh/drug therapy
dc.subject.meshCombined Modality Therapy
dc.subject.mesh/adverse effects
dc.titleFirst-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1158/1078-0432.CCR-21-1504
dc.subject.decsneoplasias
dc.subject.decs/farmacoterapia
dc.subject.decstratamiento combinado
dc.subject.decs/efectos adversos
dc.relation.publishversionhttps://doi.org/10.1158/1078-0432.CCR-21-1504
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Yap TA] Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas. [Vieito M] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Baldini C] Drug Development Department, Gustave Roussy Cancer Campus, Villejuif, France. [Sepúlveda-Sánchez JM] Hospital Universitario 12 de Octubre, Madrid, Spain. [Kondo S] National Cancer Center Hospital, Tokyo, Japan. [Simonelli M] Department of Biomedical Sciences, Humanitas University, Milan, Italy. IRCCS Humanitas Cancer Center, Humanitas Research Hospital, Milan, Italy
dc.identifier.pmid34548321
dc.identifier.wos000732481500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple